London Dec 19: A pressure-lowering eye drop has been found to greatly reduce the risk of vision loss in people with open angle glaucoma (OAG) one of the leading causes of blindness. The trial to assess the vision-preserving effect of prostaglandin analogue eye drop which is already in common use for treatment of glaucoma confirmed its efficacy. 'Our findings offer solid proof to patients and practitioners that the visual deterioration caused by glaucoma can be reduced using this treatment' said lead author David Garway-Heath from UCL (University College London) Institute of Ophthalmology. OAG currently affects around 45 million people worldwide.
